HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Submission of Matters to a Vote of Security Holders

HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Story continues below

On June 28, 2018, Helius Medical Technologies, Inc. (the “Company”) held its 2018 annual meeting of shareholders (the “Annual Meeting”). The shareholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 29, 2018.Of the 23,312,291 shares of Class A Common Stock outstanding as of the record date, 14,730,401 shares, or 63.2%, were present or represented by proxy at the Annual Meeting.Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1:Election of seven directors of the Company to serve until the 2019 annual meeting of shareholders of the Company and until their respective successors are elected and qualified. The votes were cast as follows:

Name

VotesFor

VotesWithheld

Philippe Deschamps

12,953,160

637,230

Dane C. Andreeff

13,560,927

29,463

Mitchell E. Tyler

13,121,569

468,821

Edward M. Straw

13,563,229

27,161

Blane Walter

12,947,693

642,697

Huaizheng Peng

13,589,090

1,300

Thomas E. Griffin

13,147,430

442,960

Broker Non-Votes: 1,140,011

All nominees were elected.

Proposal No. 2:Ratification of the appointment of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2018. The votes were cast as follows:

VotesFor

VotesAgainst

Abstained

Ratification of Appointment of BDO USA, LLP

14,709,175

20,767

The appointment of BDO USA, LLP was ratified.

Proposal No. 3:Approval of the reincorporation of the Company from the State of Wyoming to the State of Delaware. The votes were cast as follows:

VotesFor

VotesAgainst

Abstained

Broker

Non-Votes

Approval of Reincorporation

12,890,066

692,769

7,555

1,140,011

The reincorporation of the Company was approved.

Proposal No. 4:Ratification of the prior stock option grant to Joyce LaViscount, the Company’s Chief Financial Officer and Chief Operating Officer, to purchase 800,000 shares of common stock, on a pre-reverse stock split basis.The votes were cast as follows:

VotesFor

VotesAgainst

Abstained

Broker

Non-Votes

Ratification of Prior Option Grant

12,335,268

1,245,133

9,989

1,140,011

The option grant was ratified.

Proposal No. 5:Approval of the 2018 Equity Incentive Plan.The votes were cast as follows:

VotesFor

VotesAgainst

Broker Non-Votes

Ratification of Option Grant

12,240,545

1,349,445

1,140,011

In addition, votes cast in favor of the proposal represented 87.4% of the disinterested persons present in person of represented by proxy and entitled to vote on Proposal No. 5 (constituting a majority of such shares).Accordingly, the 2018 Equity Incentive Plan was approved.


About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.

An ad to help with our costs